2030 Biosimilars Diabetes 
European Pharmaceutical Review
JUNE 2, 2025
These include innovations in biotechnology, the expansion of biosimilar medicines and increasing investment in research and development. Ultimately, the report stated that the demand is being initiated through an increasing incidence of chronic health conditions, such as cancer, diabetes, cardiovascular conditions and autoimmune disorders.
Express Pharma
AUGUST 8, 2024
Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Business Review
APRIL 17, 2024
This partnership is set to enhance the treatment options available to diabetes patients in Brazil. It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF).
Express Pharma
MAY 13, 2025
Children and young people (CYP) living in low- and middle-income countries (LMICs) face gross inequities when it comes to the diagnosis and treatment of type 1 diabetes (T1D). Without sustainable access to diabetes care, they are unable to manage this chronic condition, leading to severe outcomes that are entirely preventable.
pharmaphorum
JUNE 16, 2025
Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
FDA Law Blog: Biosimilars
JULY 10, 2024
Another patient shared their journey with diabetes. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030. This patient had used wearable devices on their own in the past but did not understand how to use the data to manage their health.
Pharmacy Times
JUNE 18, 2025
The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. They are also more likely to have diabetes, pain, and disability than other groups. Healthy People 2030. 11 STEPPING UP A LEVEL Pharmacy teams can also speak to and for their communities. REFERENCES 1.
Expert insights. Personalized for you.
52 
Let's personalize your content